Oral Semaglutide and SELECT at DTM 2025

In this episode, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, meet in person at the Diabetes Technology Meeting (DTM) in San Francisco to discuss the latest clinical and regulatory advances surrounding semaglutide.

Key Episode Timestamps
00:00:01 Introduction
00:00:42 Oral semaglutide's FDA approval
00:02:02 The SOUL trial and Rybelsus's cardiovascular indication
00:03:35 Dosing for Rybelsus
00:06:18 The SELECT trial
00:08:29 Can GLP-1s be cardiovascular treatments?
00:14:08 Outro